VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
STAA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
STAASTAAR Surgical Company
$19.80$986M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
STAA logo

STAAR Surgical Company

STAA
NASDAQ · Medical Instruments
$19.80
At close - Sep 23, 4:00 PM EDT - USD
Market Cap$986M
P/E-12.2x
52W High$35.87
Volume845.92K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Volatile Recovery Stalls Amidst Structural Margin Resilience

STAAR Surgical's recovery appears fragile, with Q2 2026 revenue flatlining at $93.5M after a volatile period, suggesting the 111% YoY growth is largely a function of depressed prior-year comparisons. The company's core strength lies in its structurally high gr...

GrowthMixed
ProfitabilityStrained
ValuationExpensive
TechnicalsWeak
Explore valuation models
MARKET ACTION

STAA price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

8/12 Beats

EPS beat 8 of last 12 quarters

02

Valuation risk

-144% Peers

P/E is 144% below peer median

03

Market leadership

RS 26 · Lag

Laggard (Underperforming 74% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Nov 12

Market performance

Price History →

Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
STAA-16.10%
S&P 500 (^GSPC)+12.39%
1-Year Return
STAA-25.42%
S&P 500 (^GSPC)+15.77%
3-Year Return
STAA-51.88%
S&P 500 (^GSPC)+67.89%
5-Year Return
STAA-86.56%
S&P 500 (^GSPC)+66.05%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y Low
-12.2x
Forward P/E
69.6x
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-12.2x
72.6x
0th· Low
EV/EBITDA
N/A
48.5x
N/A
Price/FCF
N/A
148.9x
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$6.71-66.1%
Base (Fair)$11.13-46.5%
Bull$12.51-36.8%
$6.71 Bear$11.13 Base$12.51 Bull
Current Market Price: $19.80
Trades at a 77.9% premium to Base DCF ($11.13)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue
$239M-23.7% YoY
Net income
-$80M-298.1% YoY
Free cash flow
-$40M-422.2% YoY
Operating margin
-19.2%-15.2 pts YoY
ROIC (TTM)-13.2%
Avg ROIC 5Y-
ROE (TTM)-21.7%
Piotroski Score1 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate8/12 (67%)
Revenue Beat Rate9/12 (75%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q3 2026Latest
Aug 12, 2026
$0.16-27.7%
vs $0.22
$94M+3.2%
vs $91M
Q2 2026
May 13, 2026
$0.38+600.8%
vs $0.05
$94M+18.8%
vs $79M
Q2 2026
Mar 3, 2026
-$0.20-211.1%
vs $0.18
$58M-22.9%
vs $75M
Q4 2025
Nov 5, 2025
$0.46+155.6%
vs $0.18
$95M+25.4%
vs $76M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

5 Stories
Business Wire·Sep 10, 2026
STAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision Correction

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today released a new report entitled The Future of Refractive Surgery, the first comprehensive global market analysis showing a consistent, multi-market migration toward implantable lens correction driven by durable tailwinds on the demand and clinical sides of the market. The report examines patient.

Business Wire·Sep 8, 2026
STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of David Bailey as Chief Commercial Officer. Mr. Bailey will join STAAR's executive committee and report to Warren Foust, President and Chief Executive Officer. "David Bailey doesn't just know STAAR, he helped change the trajectory of the entir.

Business Wire·Sep 2, 2026
STAAR Surgical Names Medtech Innovator and Platform Builder Ben Park as Chief Technology Officer

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of Ben Park, Ph.D., as Chief Technology Officer. Dr. Park will join STAAR's Executive Committee and report to Warren Foust, President and Chief Executive Officer. "Evolving STAAR from a single-product focus into a multi-product platform is cent.

Defense World·Aug 27, 2026
American Capital Management Inc. Makes New $24.29 Million Investment in STAAR Surgical Company $STAA

American Capital Management Inc. purchased a new stake in STAAR Surgical Company (NASDAQ: STAA) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 846,659 shares of the medical instruments supplier's stock, valued at approximately $24,291,000. American Capital Management Inc.

Filtered for STAAR Surgical CompanyMore Headlines
04

Compare before deciding

Benchmark STAA against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for STAAR Surgical Company (STAA)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
STAA logoSTAASTAAR Surgical CompanyCurrent
$19.80$985.81M-12.22-23.72%-33.6%-21.7%—
ALGN logoALGNAlign Technology, Inc.
$148.17$10.61B26.220.9%9.99%10.09%—
LNTH logoLNTHLantheus Holdings, Inc.
$99.97$6.51B29.320.5%17.69%23.27%—
TMDX logoTMDXTransMedics Group, Inc.
$87.00$3.01B17.8637.13%22.69%32.97%—
EW logoEWEdwards Lifesciences Corporation
$86.82$49.99B47.4411.55%15.43%9.66%—
HOLX logoHOLXHologic, Inc.
$76.01$16.97B30.531.74%13.18%11.01%—

Compare STAA vs Peers

STAAR Surgical Company (STAA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ALGN

Most directly comparable listed peer for STAA.

Scale Benchmark

vs ABT

Larger-name benchmark to compare STAA against a more recognizable public peer.

Peer Set

Compare Top 5

vs ALGN, LNTH, TMDX, EW

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

STAA SEC Filings & Documents

STAAR Surgical Company (STAA) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 12, 2026·SEC

Material company update

Aug 6, 2026·SEC

Material company update

Jun 22, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 3, 2026·SEC

FY 2025

Feb 21, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 12, 2026·SEC

FY 2026

May 13, 2026·SEC

FY 2025

Nov 5, 2025·SEC

Get notified when STAA posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

STAA Frequently Asked Questions

STAAR Surgical Company (STAA) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is STAAR Surgical Company's revenue?

STAAR Surgical Company (STAA) reported $339.6M in revenue for fiscal year 2025. This represents a 705% increase from $42.2M in 1996.

How fast is STAAR Surgical Company growing?

STAAR Surgical Company (STAA) saw revenue decline by 23.7% over the past year.

Is STAA profitable?

Yes, STAAR Surgical Company (STAA) is profitable, generating $3.8M in net income for fiscal year 2025 (-33.6% net margin).

Dividend & Returns
What is STAA's return on equity?

STAAR Surgical Company (STAA) has a return on equity (ROE) of -21.7%. Negative ROE indicates the company is unprofitable.

What is STAAR Surgical Company's free cash flow?

STAAR Surgical Company (STAA) had negative free cash flow of $6.7M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in STAA back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →